Skip to main content
. 2021 Aug 2;5(15):2958–2964. doi: 10.1182/bloodadvances.2021004295

Figure 2.

Figure 2.

Best response after first-line therapy with rituximab originator (R-originator) or rituximab biosimilars (R-biosimilars). Stacked bar graph depicting tumor response in patients with diffuse large B-cell lymphoma treated with rituximab originator (R-originator) or rituximab biosimilars (R-biosimilars) combined with standard CHOP chemotherapy regimens.